JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) AI Stock Analysis

• Market Cap: ₹295.77B
• Dividend Yield: 0.86%
• Average Volume (3M): 2.67K
• Price to Earnings (P/E): 41.0
• Beta (1Y): 0.58
• Revenue Growth: 10.25%
• EPS Growth: 17.01%
• Country: IN
• Employees: 5,311
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.30
• Shares Outstanding: 156,650,960
• 10 Day Avg. Volume: 4,569
• 30 Day Avg. Volume: 2,671
• PEG Ratio: 1.96
• Price to Book (P/B): 7.17
• Price to Sales (P/S): 6.28
• P/FCF Ratio: 30.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ₹1,815.00 ▼(-1.78% Downside)

JB Chemicals & Pharmaceuticals Ltd. has a strong financial foundation with impressive revenue growth and profitability. However, the stock's valuation appears high, and technical indicators suggest a neutral market sentiment. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Revenue Growth

The strong revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability.

Financial Stability

A solid balance sheet with low leverage enhances financial flexibility, enabling strategic investments and resilience against economic downturns.

Cash Generation

Efficient cash generation supports ongoing operations and future investments, ensuring the company can capitalize on growth opportunities.

Negative Factors

Capital Expenditure Management

Inconsistent capital expenditure management may impact cash flow stability, potentially hindering long-term growth and investment capacity.

Valuation Concerns

High valuation compared to peers may limit upside potential and attract scrutiny, affecting investor sentiment and future capital raising.

Earnings Call Insights

Lack of earnings call insights limits transparency and investor understanding of strategic direction, potentially affecting confidence and stock performance.

JB Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners. Further, the company provides its services in gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India.

How the Company Makes Money

JBCHEPHARM generates revenue through multiple streams, primarily from the sale of its pharmaceutical formulations and active pharmaceutical ingredients. The company markets its products through a well-established distribution network, which includes both wholesalers and retail pharmacies. Additionally, JBCHEPHARM earns revenue from exports, significantly contributing to its earnings as it caters to various international markets. The company's strategic partnerships with healthcare providers and distributors further enhance its market presence and revenue potential. Moreover, JBCHEPHARM invests in research and development to innovate and expand its product portfolio, thereby driving growth and increasing its competitive advantage in the pharmaceutical industry.

JB Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

JB Chemicals & Pharmaceuticals Ltd. demonstrates strong financial performance with robust revenue growth, efficient cost management, and solid profitability metrics. The balance sheet reflects low leverage and high equity, ensuring financial stability. Cash flows are strong, though capital expenditure management requires attention for sustained growth.

Income Statement

JB Chemicals & Pharmaceuticals Ltd. has demonstrated strong revenue growth with a notable increase in total revenue from INR 24.2 billion to INR 39.2 billion in the latest annual period. The gross profit margin is impressive, reflecting efficient cost management, and the net profit margin has improved, indicating enhanced profitability. The EBIT and EBITDA margins also show a positive trajectory, supporting the company's stable financial performance.

Balance Sheet

The company's balance sheet is solid with a low debt-to-equity ratio, showcasing financial stability and low leverage risk. The return on equity is commendable, reflecting effective utilization of shareholder funds. The equity ratio is strong, indicating a healthy proportion of assets financed by equity. Overall, the balance sheet reflects financial robustness with moderate risk.

Cash Flow

JB Chemicals & Pharmaceuticals Ltd. exhibits a strong operating cash flow relative to net income, highlighting efficient cash generation from operations. The free cash flow has grown significantly, which bodes well for future investments and shareholder returns. However, fluctuations in capital expenditures could pose potential risks to sustaining cash flow growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.08B	39.18B	34.84B	31.17B	24.24B	20.06B
Gross Profit	22.34B	26.01B	13.46B	11.14B	15.61B	12.88B
EBITDA	10.81B	10.32B	9.33B	7.04B	5.82B	6.72B
Net Income	6.85B	6.60B	5.53B	4.10B	3.85B	4.48B
Balance Sheet
Total Assets	0.00	42.74B	39.94B	35.54B	26.07B	22.38B
Cash, Cash Equivalents and Short-Term Investments	4.50B	4.50B	4.60B	2.69B	566.50M	6.94B
Total Debt	0.00	278.90M	3.78B	5.72B	545.59M	449.88M
Total Liabilities	-34.33B	8.40B	10.71B	10.74B	4.69B	4.25B
Stockholders Equity	34.33B	34.33B	29.23B	24.80B	21.34B	18.10B
Cash Flow
Free Cash Flow	0.00	8.05B	5.39B	-1.39B	-5.37B	2.67B
Operating Cash Flow	0.00	9.02B	8.01B	6.26B	1.70B	3.15B
Investing Cash Flow	0.00	-2.96B	-4.08B	-9.62B	23.20M	-2.31B
Financing Cash Flow	0.00	-5.80B	-3.41B	3.57B	-1.38B	-874.23M

JB Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1847.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JBCHEPHARM, the sentiment is Positive. The current price of 1847.8 is above the 20-day moving average (MA) of 1826.61, above the 50-day MA of 1793.75, and above the 200-day MA of 1700.67, indicating a bullish trend. The MACD of 29.77 indicates Negative momentum. The RSI at 62.99 is Neutral, neither overbought nor oversold. The STOCH value of 82.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JBCHEPHARM.

JB Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AJANTPHARM	72 Outperform	₹345.78B	35.51	―	1.04%	10.74%	11.91%
PFIZER	69 Neutral	₹222.87B	26.55	―	0.69%	6.13%	35.83%
JBCHEPHARM	66 Neutral	₹295.77B	40.98	―	0.86%	10.25%	17.01%
GLAND	63 Neutral	₹276.91B	35.03	―	1.07%	-1.51%	14.27%
GLENMARK	53 Neutral	₹566.35B	56.08	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JB Chemicals & Pharmaceuticals Ltd. Corporate Events

JB Chemicals Allots Shares Under Employee Stock Option Scheme

JB Chemicals & Pharmaceuticals Ltd. has announced the allotment of 21,056 equity shares following the exercise of stock options by an employee under the company’s Employee Stock Option Scheme, 2021. This allotment has resulted in an increase in the company’s issued, subscribed, and paid-up capital, reflecting a strategic move to incentivize and retain talent within the organization.

Torrent Pharmaceuticals Announces Open Offer for J.B. Chemicals & Pharmaceuticals

Torrent Pharmaceuticals Limited has announced an open offer to acquire up to 26% of the expanded share capital of J.B. Chemicals & Pharmaceuticals Limited, a move in compliance with the SEBI (SAST) Regulations. This acquisition, priced at INR 1,639.18 per share, is significant as it reflects Torrent Pharmaceuticals’ strategic expansion efforts in the pharmaceutical industry, potentially impacting the market dynamics and shareholder value of J.B. Chemicals & Pharmaceuticals.

JB Chemicals Relocates Registered Office to Gujarat

JB Chemicals & Pharmaceuticals Limited has announced the relocation of its registered office from Maharashtra to Gujarat. This move, disclosed in compliance with SEBI regulations, was published in major newspapers, indicating a strategic shift that could impact the company’s operational dynamics and stakeholder engagement.